These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25452650)

  • 1. Authors' responses in response to the letter from Ambrose.
    Meissner HC; Brady MT; Byington CL; Kimberlin DW; Lieberthal AS; Maldonado YA; Ralston SL; Winterstein A
    Pediatrics; 2014 Dec; 134(6):e1782-3. PubMed ID: 25452650
    [No Abstract]   [Full Text] [Related]  

  • 2. In response to the letter from Braden.
    Meissner HC; Hennessy S; Rowe E; Brady MT
    Pediatrics; 2014 Dec; 134(6):e1783-4. PubMed ID: 25452651
    [No Abstract]   [Full Text] [Related]  

  • 3. Palivizumab and emerging therapies for respiratory syncytial virus.
    Hoopes JM; Makari D; Groothuis J
    Expert Opin Biol Ther; 2012 May; 12(5):547-8; author reply 549. PubMed ID: 22348302
    [No Abstract]   [Full Text] [Related]  

  • 4. Respiratory syncytial virus and recurrent wheeze.
    Blanken MO; Rovers MM; Bont L;
    N Engl J Med; 2013 Aug; 369(8):782-3. PubMed ID: 23964947
    [No Abstract]   [Full Text] [Related]  

  • 5. Respiratory syncytial virus and recurrent wheeze.
    Brand PL
    N Engl J Med; 2013 Aug; 369(8):782. PubMed ID: 23964948
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: technical report.
    Braden NJ
    Pediatrics; 2014 Dec; 134(6):e1781. PubMed ID: 25452649
    [No Abstract]   [Full Text] [Related]  

  • 7. Palivizumab prophylaxis during respiratory syncytial virus outbreak in the neonatal intensive care unit.
    Alan S; Cakır U; Erdeve O; Atasay B; Arsan S
    Turk J Pediatr; 2013; 55(2):237-8. PubMed ID: 24192692
    [No Abstract]   [Full Text] [Related]  

  • 8. Respiratory syncytial virus prophylaxis reduces chronic respiratory morbidity in prematurely born infants.
    Greenough A
    Evid Based Med; 2014 Apr; 19(2):65. PubMed ID: 24142143
    [No Abstract]   [Full Text] [Related]  

  • 9. Respiratory syncytial virus infection is linked to recurrent wheezing in healthy premature infants.
    Escobar GJ
    J Pediatr; 2013 Nov; 163(5):1531. PubMed ID: 24160662
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey.
    Paes B; Lanctôt K
    Turk J Pediatr; 2013; 55(5):564-7. PubMed ID: 24382545
    [No Abstract]   [Full Text] [Related]  

  • 11. Palivizumab prophylaxis during respiratory syncytial virus outbreak in neonatal intensive care unit: author's reply.
    Oncel MY; Dizdar EA; Dilmen U
    Turk J Pediatr; 2013; 55(2):239. PubMed ID: 24205516
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey: author's reply.
    Oncel MY; Alyamaç-Dizdar E; Erdeve O; Oğuz S; Dilmen U
    Turk J Pediatr; 2013; 55(5):568. PubMed ID: 24401320
    [No Abstract]   [Full Text] [Related]  

  • 13. Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.
    Smart KA; Lanctôt KL; Paes BA
    Can Fam Physician; 2010 Oct; 56(10):988-91. PubMed ID: 20944037
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe RSV disease in preterm infants born at 29 to 35 weeks' gestation in the United States.
    Ambrose CS
    Pediatrics; 2014 Dec; 134(6):e1781. PubMed ID: 25452648
    [No Abstract]   [Full Text] [Related]  

  • 15. Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?
    Elnazir B; Oni O; Hassan T; Greally P; Paes B
    J Paediatr Child Health; 2012 Nov; 48(11):1033-8. PubMed ID: 23126393
    [No Abstract]   [Full Text] [Related]  

  • 16. Authors' response re: Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.
    Meissner HC; Kimberlin DW
    Pediatrics; 2014 Apr; 133(4):e1101-3. PubMed ID: 24692038
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibody against RSV helps prevent wheeze in infants.
    BMJ; 2013 May; 346():f3089. PubMed ID: 23678095
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to respiratory synctial virus.
    Hampp C; Winterstein AG
    South Med J; 2008 Feb; 101(2):212-3; author reply 213-4. PubMed ID: 18364631
    [No Abstract]   [Full Text] [Related]  

  • 19. Palivizumab use in Japanese infants and children with immunocompromised conditions.
    Mori M; Onodera M; Morimoto A; Kosaka Y; Morio T; Notario GF; Sharma S; Saji T
    Pediatr Infect Dis J; 2014 Nov; 33(11):1183-5. PubMed ID: 24830698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory syncytial virus: different criteria for palivizumab use in different areas?
    Mitchell I
    South Med J; 2007 Jul; 100(7):661-2. PubMed ID: 17639741
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.